In brief
- A randomized, placebo-controlled phase IIa trial published in Nature Medicine (2026) tested a single dose of intravenous DMT in 34 people with moderate to severe major depression.
- The group receiving DMT showed significantly greater improvement than the placebo group on the MADRS scale: a difference of -7.35 points at two weeks (p=0.023) and an even greater difference at one week (-10.75; p=0.002).
- These results are promising but preliminary: the sample size is small, the effect was measured in the short term, and the drug was administered in a clinical setting with psychological support. This is not proof of a “cure.”
Dimethyltryptamine (DMT), one of the shortest-acting psychedelics, has just passed a test that almost no other compound of its kind has cleared with such rigor: a randomized, placebo-controlled clinical trial for major depression. The results, published in Nature Medicine, indicate that a single intravenous dose reduced depressive symptoms rapidly and with statistical significance compared to a placebo. It is an encouraging signal, but one that should be read with the caution required for an early-phase study.
The study
The paper, authored by David Erritzoe, Tommaso Barba, Robin Carhart-Harris, David Nutt, and collaborators from Imperial College London alongside the sponsor’s team (SPL026), was published in Nature Medicine on February 16, 2026. This was a phase IIa, double-blind, randomized, placebo-controlled trial—the design considered the gold standard for evaluating whether a drug truly works rather than succeeding due to suggestion or chance. The study included 34 adults with moderate or severe major depression. Each participant received a single dose of 21.5 mg of DMT (fumarate) intravenously, infused over ten minutes, or a placebo. The session was accompanied by psychotherapeutic support focused on psychological flexibility, both during preparation and subsequent integration. Following the blinded phase, an open-label phase allowed some participants to receive a second dose.
What was found
The primary outcome measure was the MADRS scale, one of the most widely used tools for quantifying the severity of depression. At two weeks, those who received DMT improved by an average of 7.35 points more than the placebo group (95% confidence interval: -13.62 to -1.08; p=0.023; effect size d=0.82). The effect was even greater one week after the session: a difference of 10.75 points (95% CI: -16.95 to -4.55; p=0.002; d=1.09). In other words, the improvement appeared early, in the first days following administration. Combining all participants who received one or two doses, the remission rate was 40% and the response rate was 44% at three months.
Regarding safety, there were no serious adverse events. Most effects were mild or moderate: pain at the infusion site (13 cases after DMT vs. 3 with placebo), nausea (6 after DMT), and anxiety (6 after DMT), all consistent with the intense and brief nature of the experience. The second dose was tolerated even better than the first.
What it means (and what it doesn’t)
The most striking data point is the speed. Conventional antidepressants often take weeks to take effect, whereas here, improvement was observed within days after a single session. This, combined with the fact that DMT acts for minutes rather than hours, makes it an attractive candidate for investigation in a clinical format that is more manageable than other long-acting psychedelics.
However, we must be honest in both directions. This is a phase IIa trial with only 34 people: a small sample size, with even smaller subgroups and little room for fine-grained analysis. The primary effect was measured in the short term (two weeks), and although there is follow-up data at three months, the actual long-term durability remains to be confirmed in larger studies. The sample was also not very diverse (approximately 88% of participants were of European descent) and excluded people with a history of serious suicide attempts, so the results cannot be extrapolated to every patient. The authors themselves note that they did not evaluate whether the “blind” remained intact—a chronic challenge in psychedelic research, as the subjective effect is difficult to mask—nor could they fully separate the role of the drug from the role of the psychological support that accompanied it.
That last point is key and often gets lost in headlines: the DMT in this trial was not administered in isolation, but within a careful therapeutic framework, including preparation and integration. It is not a pill to be taken at home, but a supervised clinical intervention. Presenting it as a “miracle” or a “cure” would be as unrigorous as dismissing it due to prejudice. What this work shows is a promising signal that justifies further research, with larger, more diverse trials and longer follow-ups, before drawing conclusions about its real-world use. From a regulatory standpoint, DMT remains a controlled substance in most countries today; its use is limited to the context of authorized research. That is the terrain where, for now, this evidence makes sense.
Source
- Erritzoe D, Barba T, Benway T, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nature Medicine, 2026. DOI: 10.1038/s41591-025-04154-z
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
